Table 1.
Demographics and Clinical Characteristics of Eligible Patients
| Characteristic | Validation Cohort (N = 188) |
|
|---|---|---|
| No. of Patients | % | |
| Patient age, years | ||
| Median | 61 | |
| Range | 42-78 | |
| IQR (Q1-Q3) | 56-66 | |
| Preoperative PSA, ng/mL | ||
| Median | 7.8 | |
| Range | 0.4-80.4 | |
| IQR (Q1-Q3) | 5.3-12.3 | |
| Pathologic Gleason score | ||
| ≤ 6 | 28 | 14.9 |
| 7 (3 + 4) | 60 | 31.9 |
| 7 (4 + 3) | 50 | 26.6 |
| ≥ 8 | 48 | 25.5 |
| Unknown | 2 | 1.1 |
| Extraprostatic extension | 136 | 72.3 |
| Seminal vesicle invasion | 65 | 34.6 |
| Surgical margins | 147 | 78.2 |
| Pre-RT PSA, ng/mL | ||
| Median | 0.2 | |
| Range | 0-39 | |
| IQR (Q1-Q3) | 0.1-0.7 | |
| RT modality | ||
| Adjuvant RT | 96 | 51.1 |
| Salvage RT | 89 | 47.3 |
| Unknown | 3 | 1.6 |
| ADT | 56 | 29.8 |
| Time from RP to RT, months | ||
| Median | 5 | |
| Range | 1-159.7 | |
| IQR (Q1-Q3) | 3.6-15.3 | |
Abbreviations: ADT, androgen-deprivation therapy; IQR, interquartile range; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiation therapy; Q, quartile.